Have you been diagnosed with Molecular Low-Risk Early-Stage Breast Cancer? If so, you may be able to take part in a research study using lower dose of tamoxifen, to evaluate if it is a better treatment than usual hormonal therapy in women with low-risk, early-stage breast cancer.

Are you an adult with an intellectual disability (ID/D) age 18 to 30 years? Would you and your adult care partner like to participate in a one-hour zoom interview together to answer questions that can help researchers learn about school and community experiences and technology use that helps people with ID/D transition to adulthood? Digitial gift card compensation provided to both participants.

The purpose of this study is to estimate the probability of participants being off all anti-cancer treatment (with the exception of endocrine therapy for those with ER+ disease) and free of disease progression 4 years from study entry.

Do you have lupus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM)? You may be eligible for a new CAR-T therapy conducted at University of North Carolina at Chapel Hill. Please reach out to learn more about this new innovative treatment.

Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.

The purpose of this study is to test the safety and eff ectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan; or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating your type of cancer. Additional information collected from this study may also help inform the future use of these drugs.

Do you have metastatic or incurable, recurrent head and neck cancer? If so, you may be able to participate in a research study to find out if a new investigational drug, in combination with pembrolizumab, can help people with advanced head and neck cancer.

Have you been diagnosed with Ovarian Cancer? Have you received cytoreductive surgery? If so, you may be able to take part in a study on a new ovarian cancer treatment. We want to find out if taking a medicine called Olaparib for one year works as well as the usual treatment for ovarian cancer. We also want to see if Olaparib can help stop the cancer from growing or coming back.

Have you been diagnosed with early stage triple negative breast cancer and not yet received treatment? If so, you may be eligible for a trial comparing the use two different regimens of chemotherapy-immunotherapy treatments prior to surgery.

This study is assessing the usefulness of a text message based intervention to reduce excessive alcohol use among young adults ages 18-25. Participants will attend a Baseline Session over Zoom where they will complete a 25-minute survey and learn more about study procedures. Then, participants will receive daily prompts to their personal cellphone Wednesday-Sunday for 4 weeks. After the 4-week trial, participants will attend 1 focus group over Zoom to share their experiences in the study.